McIntyre, Freedman & Flynn Investment Advisers’s Bristol-Myers Squibb BMY Stock Holding History

McIntyre, Freedman & Flynn Investment Advisers’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,000	Closed	-$485K	–	86
2026 Q1	$485K	Hold	8,000	–	–	0.28%	56
2025 Q4	$432K	Hold	8,000	–	–	0.27%	57
2025 Q3	$361K	Buy	8,000 +2,000	+33%	+$93.4K	0.22%	59
2025 Q2	$278K	Buy	6,000 +1,000	+20%	+$49.1K	0.2%	56
2025 Q1	$305K	Sell	5,000 -52	-1%	-$3.03K	0.22%	54
2024 Q4	$286K	Sell	5,052 -1,000	-17%	-$55.9K	0.21%	55
2024 Q3	$313K	Sell	6,052 -1,000	-14%	-$46.9K	0.22%	53
2024 Q2	$293K	Buy	+7,052	New	+$316K	0.21%	54
2023 Q4	–	Sell	-8,051	Closed	-$467K	–	67
2023 Q3	$467K	Buy	8,051 +1,000	+14%	+$61.3K	0.39%	49
2023 Q2	$451K	Buy	7,051 +900	+15%	+$60.4K	0.39%	46
2023 Q1	$426K	Buy	6,151 +1,100	+22%	+$77.6K	0.36%	48
2022 Q4	$363K	Buy	+5,051	New	+$381K	0.3%	50

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

McIntyre, Freedman & Flynn Investment Advisers's BMY Position: Q2 2026 in Review

McIntyre, Freedman & Flynn Investment Advisers sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 8,000 shares — an estimated $485K sold.

McIntyre, Freedman & Flynn Investment Advisers first reported a position in BMY in Q4 2022 and held it in 12 quarters. The position peaked at $485K in Q1 2026. 1,993 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

McIntyre, Freedman & Flynn Investment Advisers reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
McIntyre, Freedman & Flynn Investment Advisers sold 8,000 Bristol-Myers Squibb shares in Q2 2026, an estimated $485K.
McIntyre, Freedman & Flynn Investment Advisers first reported a position in Bristol-Myers Squibb in Q4 2022 and held it in 12 quarters.
McIntyre, Freedman & Flynn Investment Advisers's Bristol-Myers Squibb position peaked at $485K in Q1 2026.
1,993 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on McIntyre, Freedman & Flynn Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.